Isogenica Ltd., a leader in the use of synthetic biology and in vitro display for the discovery and optimisation of novel biotherapeutics, today announced the appointment of Dr Bjӧrn Cochlovius to Isogenica’s Board of Directors (the “Board”) effective immediately.
Dr Cochlovius joins Isogenica as a non-executive director replacing Dr Gӧran Forsberg, who stepped down from the Board on October 11, 2019. Dr Forsberg has served as a non-executive director since 2011. Dr Forsberg said “During the last couple of years Isogenica has become an established actor in antibody discovery with strong opportunities to expand from the current platform. I wish Isogenica every success for the future.” The Chairman and the Board thank Dr Forsberg for his invaluable support and guidance over the last eight years.
Bjӧrn Cochlovius most recently served as Senior Director of Development (Strategy) at AbbVie and brings 20 years of biopharmaceutical discovery, clinical development and commercial experience to the Board. Dr Cochlovius previously held positions in research and development, business development and mergers and acquisitions at companies including Affitech AS, Roche and Otsuka. Dr Cochlovius started his career developing diabodies and tandem diabodies: fully human recombinant bispecific antibodies. He became the youngest department head at the German Cancer Research Centre (dkfz), after a PhD in immunology and oncology obtained at the Universität des Saarlandes.
“We are delighted to welcome Dr Bjӧrn Cochlovius to the Board” said Jan-Olof Lundin, Non-executive Chairman of Isogenica. “Strengthening our team with this non-executive director appointment is part of our core strategy as we increase the scope of our activities to pursue broader, deeper relationships with biopharmaceutical partners.”
“The company is building from strong foundations with impressive data emerging from discovery programmes using its fully synthetic LlamdATM single domain library” said Dr Cochlovius. “I look forward to working with fellow Board members and the management team to take the company to the next level.”
Isogenica is developing LlamdATM (single domain VHH) and AlexandriaTM (human Fab) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display andColibraTM technologies to accelerate the discovery and development process. Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”
For more information, visit www.isogenica.com